![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChemCID | |
ChemSpider | |
UNII |
|
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C11H13NO2 |
Molar mass | 191.230 g·mol−1 |
3D model (JSmol) | |
|
6,7-Methylenedioxy-2-aminotetralin (MDAT) is adrug developed in the 1990s by a team atPurdue University led byDavid E. Nichols.[1] It appears to act as aserotonin releasing agent based on rodent drug discrimination assays comparing it toMDMA, in which it fully substitutes for, and additionally lacks any kind ofserotonergicneurotoxicity.[1] Hence, MDAT is considered likely to be a non-neurotoxic, putativeentactogen in humans.